acyl-CoA synthetase long chain family member 5Genealiases: ACS2 · ACS5 · DIAR13 · FACL5
Q-omics provides the consensus-scored ACSL5 profile across patient tissues and cancer cell-line models. ACSL5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ACSL5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ACSL5 protein abundance shows 25,568 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, THCA, and LSCC as cancer lineages where ACSL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSL5 survival associations across molecular data types. ACSL5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSL5 RNA expression–survival associations across cancer types. High ACSL5 expression shows unfavorable associations in LUSC and THYM, but favorable associations in MESO, UCEC, SKCM and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ACSL5 RNA expression.
This table summarizes ACSL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSL5 shows lower tumor expression in LUSC, BRCA, KIRP and KICH and higher tumor expression in THCA and KIRC. The THCA box plot shows higher ACSL5 RNA expression in tumor versus normal tissue (log2 FC = +0.973, t-test p < 0.001).
This table shows molecular features associated with ACSL5 in patient tissues and cancer cell lines. In patient samples, ACSL5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
